ArticleCJC open2026
Medium to Long-Term Patient-Oriented Effectiveness of Surgical or Percutaneous Revascularization in Diabetes and Severe Coronary Artery Disease.
Article in CJC open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In patients with diabetes and coronary artery disease, coronary artery bypass grafting (CABG) confers a long-term survival advantage over percutaneous coronary intervention (PCI); however, a knowledge gap remains regarding patient-centred outcomes. We therefore compared patient-defined adverse cardiovascular and noncardiovascular events (PACE) after CABG vs PCI in diabetic patients. Methods: We conducted a population-based, retrospective cohort study of all diabetic patients who underwent CABG or PCI between October 2008 and December 2018 in Ontario, Canada. The primary outcome was PACE, defined as the composite of severe stroke requiring hospitalization > 14 days or inpatient rehabilitation, ventilator dependence, heart failure hospitalization, long-term care admission, and new-onset dialysis. Secondary outcomes included all-cause mortality and individual PACE components. Overlap weighting using propensity scores was performed to account for baseline differences between groups. Cumulative incidence functions were estimated, and groups were compared using cause-specific hazard models (with death as a competing risk) and Cox proportional hazards models. Results: A total of 58,826 patients (25,751 CABG; 33,075 PCI) were followed for a mean of 4.7 years (standard deviation 3.1; maximum 11.5). Rates of PACE were lower after CABG vs PCI over 1-5 years postintervention (1-year HR 0.88 [95% CI 0.77-1.00]; 5-year HR 0.83 [95% CI 0.71-0.97]). Rates of death were lower after CABG during the first 8 years (30-day HR 0.61 [95% CI 0.50-0.74]; 5-year HR 0.71 [95% CI 0.63-0.80]; 8-year HR 0.82 [95% CI 0.69-0.98]). Conclusions: We observed lower rates of PACE and all-cause mortality in diabetic patients within the first 5 years after CABG, compared to PCI. Findings could be used to inform shared decision-making to achieve outcomes most valued by patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.